Ireland
--:--IST
Latest
Clinical Trials in Switzerland / NCT06826105
Recruiting Not applicable

Pancrelipase With Nutritional Supplement in Patients at Risk of Malnutrition (EFFORT-ENZO)

NCT06826105 · tracked via the Priya Life Science Switzerland tracker
Sponsor
Philipp Schuetz
Phase
Not applicable
Started
2025-09-22
Last updated
2026-09-22

Condition(s) studied

Malnutrition

Investigational drug(s) / intervention(s)

Zenpep →Placebo

Zenpep: two capsules (each containing 15000 USP units of lipase) together with nutritional supplements

Placebo: two capsules (containing placebo) together with nutritional supplements

Study summary

This study investigates if pancreatic enzymes in combination with oral nutritional supplement can improve nutrient bioavailability in older people with malnutrition or at risk of malnutrition.

Eligibility

Sex
ALL
Min age
60 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Informed Consent as documented by signature * Male or female 60 years of age or older * Hospitalized at site * Nutrition Risk Screening 2002 (NRS-2002) ≥ 3 * eGFR ≥ 30 mL/min/1.73 m2 (EPI-CKD) based on medical history (no older than 6 months) * Ability to eat orally Exclusion Criteria: * Patients with acute cardiovascular event ≤ 2 days * Patients with terminal conditions * Patients diagnosed with pancreatic exocrine insufficiency (EPI) treated with pancreatic enzyme replacement therapy (PERT) * Patients having a planned transplant or new-onset dialysis in the next 6 months. * Patients having a colectomy, resection of the small intestine or cholecystectomy * Known hypersensitivity to any of the substances or excipients of the ONS or the medicinal product

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Kantonsspital Aarau Aarau Switzerland Recruiting

More Philipp Schuetz trials in Switzerland

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06826105 on ClinicalTrials.gov ↗ ← All trials in Switzerland